Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer

Fig. 5

In vivo antitumor effect and safety. A Tumor model establishment and drug administration time diagram. B Tumor images after 21 days of treatment in different groups. C Tumor weight after 21 days of treatment in different groups. D Photographs of tumor-bearing mice. E Tumor H&E staining in different treatment groups. Scale bars: 100 µm. F Tumor inhibition rate after 21 days of treatment in different groups. G Tumor Ki-67 immunohistochemical imaging in different treatment groups. Scale bars: 100 µm. H The change curve of tumor volume of tumor-bearing mice during 18 days of treatment. I The weight change curve of tumor-bearing mice during 18 days of treatment. J H&E staining of the main organs in different treatment groups. Scale bars: 100 µm. All data represented the mean ± SD (n = 3) (*p < 0.05; **p < 0.01; ***p < 0.001)

Back to article page